Researchers at NYU College of Dentistry have uncovered what may be biologically driving oral health issues unique to Down syndrome.

 

Their study, published in Cell Reports, describes a molecular mechanism—a defect in calcium signaling—behind low saliva production, along with other factors that may contribute to gum disease.

New research published in Nature is first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor, with peripheral biomarker changes and associated tumor biology. HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS). A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens.

Researchers have revealed the structures underlying a family of debilitating genetic disorders. They discovered how genetic mutations disrupt communication links between nerves and muscles. The findings open pathways for developing customized medicines tailored to each patient’s genetic mutations.